Indication
Rectal Adenocarcinoma
34 clinical trials
27 products
17 drugs
Clinical trial
An Open-Label Study of GV20-0251 in Patients With Advanced and/or Refractory Solid Tumor MalignanciesStatus: Recruiting, Estimated PCD: 2025-12-15
Product
GV20-0251Clinical trial
Organ Preservation for Patients With Locally Advanced Rectal Adenocarcinoma: Evaluating the Efficacy of Short Course Radiation Therapy Followed by FOLFOX or CapeOXStatus: Recruiting, Estimated PCD: 2025-10-15
Product
CapecitabineDrug
5-FUDrug
FOLFOXIRIDrug
mFOLFOX6Clinical trial
MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal CancerStatus: Recruiting, Estimated PCD: 2025-06-01
Product
FOLFOXClinical trial
3T: A Phase II Single Arm Open Label Study of Tucatinib Combined With Trastuzumab and TAS-102 in Molecularly Selected Patients With HER2+ Metastatic Colorectal CancerStatus: Not yet recruiting, Estimated PCD: 2024-05-30
Drug
TrastuzumabProduct
Trifluridine and TipiracilDrug
TucatinibClinical trial
Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma (PRECAM): An Open Label, Prospective, Single Arm Clinical TrialStatus: Active (not recruiting), Estimated PCD: 2023-03-31
Drug
EnvafolimabClinical trial
A Phase I Clinical Trial of Regorafenib, Nivolumab, and Ipilimumab in Advanced Chemotherapy Resistant Metastatic MSS Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Product
IpilimumabProduct
NivolumabDrug
RegorafenibClinical trial
Organ Preservation With Active Surveillance After Chemoradiation in Rectal Cancer (OPTION)Status: Recruiting, Estimated PCD: 2026-10-31
Drug
CisplatinClinical trial
Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Product
LY2157299Clinical trial
INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer, a Phase II Randomized Multi-center Trial With and Without APX005M, an Anti-CD40 AgonistStatus: Active (not recruiting), Estimated PCD: 2025-09-01
Product
APX005MProduct
mFOLFOXClinical trial
Phase Ib/II Trial of SX-682 in Combination With Nivolumab for Refractory RAS Mutated (RAS) Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) (STOPTRAFFIC-1)Status: Recruiting, Estimated PCD: 2025-01-31
Product
SX-682Clinical trial
Phase 1b Study to Assess the Safety of Neoadjuvant TAS-102 (Trifluridine/Tipiracil) With Concurrent Radiation in Previously Untreated Resectable Stage II and Stage III Rectal Cancer (FIERCE)Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Locally Advanced Rectal CancerStatus: Not yet recruiting, Estimated PCD: 2024-05-31
Clinical trial
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 AmplificationStatus: Active (not recruiting), Estimated PCD: 2022-11-01
Product
CetuximabClinical trial
A Phase II Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid TumorsStatus: Recruiting, Estimated PCD: 2026-11-30
Product
TSR-042Clinical trial
Non-Operative Management and Early Response Assessment in Rectal CancerStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
MRI Guided Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma to Enhance Complete ResponseStatus: Active (not recruiting), Estimated PCD: 2024-10-09
Drug
UTD1Product
IrinotecanClinical trial
Phase I/II Trial of Encorafenib, Cetuximab, and Nivolumab in Microsatellite Stable BRAFV600E Metastatic Colorectal Cancer (BMS-MDACC CA209-8P6/ARRAY IST-818-101X)Status: Recruiting, Estimated PCD: 2025-06-30
Product
EncorafenibClinical trial
Randomized Phase II Trial of Encorafenib and Cetuximab With or Without Nivolumab (NSC #748726) for Patients With Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal CancerStatus: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
Evaluating Novel Therapies and ctDNA as a Marker in Curatively-Treated Gastrointestinal Cancers With Microscopic Residual DiseaseStatus: Recruiting, Estimated PCD: 2026-12-01
Drug
AtezolizumabClinical trial
STAR-TREC: Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?Status: Recruiting, Estimated PCD: 2024-08-01
Product
Capecitabine + RadiotherapyProduct
PertuzumabClinical trial
A Phase II Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2025-02-09
Product
CabozantinibDrug
T-VECClinical trial
A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal CancerStatus: Terminated, Estimated PCD: 2021-07-31
Product
SavolitinibClinical trial
PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy After Progression on Anti-EGFR Therapy in Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Product
PanitumumabClinical trial
Modulation of the FOLFIRI-based Standard First-line Therapy With Cetuximab, Controlled by Monitoring the RAS (Rat Sarcoma) Mutation Load by Liquid Biopsy in RAS-mutated mCRC (Metastatic Colorectal Cancer): A Randomized Phase II Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab (MoLiMoR)Status: Active (not recruiting), Estimated PCD: 2024-07-22
Clinical trial
A Phase II Study of Induction Tucatinib and Trastuzumab With Total Neoadjuvant Therapy for Locally Advanced HER2-amplified Rectal AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal CancerStatus: Completed, Estimated PCD: 2020-04-21
Drug
AN0025Drug
fluorouracilProduct
VeliparibClinical trial
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)Status: Completed, Estimated PCD: 2017-09-01
Product
Clobetasol PropionateClinical trial
A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal AdenocarcinomaStatus: , Estimated PCD: 2026-12-31
Drug
LurbinectedinClinical trial
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT-803Status: Completed, Estimated PCD: 2021-06-01
Product
Natural Killer CellsProduct
ALT803Clinical trial
CATRIPCA - A Phase I Study of PD1 Monoclonal Antibody (Pembrolizumab) In Combination With a IAP Antagonist (Debio 1143) In (Exocrine) Pancreatic And Colorectal Non MSI-high Advanced/Metastatic Adenocarcinoma.Status: Completed, Estimated PCD: 2022-05-30
Product
DEBIO1143Clinical trial
A Phase Ib/II Trial of M7824 in Solid Tumors With Microsatellite Instability With Consensus Molecular Subtype 4 Metastatic Colorectal Cancer in Combination With Radiation, or in Colorectal Cancer Patients With Detectable Circulating Tumor DNA Following Definitive TherapyStatus: Active (not recruiting), Estimated PCD: 2023-08-01
Product
M7824Clinical trial
A Phase I Study of Talimogene Laherparepvec (Talimogene Laherparepvec) With Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the RectumStatus: Terminated, Estimated PCD: 2022-03-22
Product
Talimogene LaherparepvecClinical trial
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Pre-operative ChemoradiationStatus: Terminated, Estimated PCD: 2015-04-01
Drug
oxaliplatinDrug
bevacizumabClinical trial
The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma: A Prospective, Single-arm StudyStatus: Recruiting, Estimated PCD: 2025-01-01
Drug
Adebrelimab